A Stable Micellar Formulation of RAD001 for Intracerebroventricular Delivery and the Treatment of Alzheimer’s Disease and Other Neurological Disorders
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242417478 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Laura Gianessi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy. Hauptthemen laut MEDLINE: Everolimus, Alzheimer Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione SMuovilavita - Vicenza, “SMuovilavita Foundation”, NPO, Italy, “Associazione Sclerosi Tuberosa”, NPO, Italy.
Themen: Demenz
Abstract (Originalsprache)
A large body of evidence, replicated in many mouse models of Alzheimer’s disease (AD), supports the therapeutic efficacy of the oral mammalian target of rapamycin inhibitors (mTOR-Is). Our preliminary data show that intracerebroventricular (ICV) administration of everolimus (RAD001) soon after clinical onset greatly diminished cognitive impairment and the intracellular beta amyloid and neurofibrillary tangle load. However, RAD001 shows >90% degradation after 7 days in solution at body temperature, thus hampering the development of proper therapeutic regimens for patients. To overcome such a drawback, we developed a stable, liquid formulation of mTOR-Is by loading RAD001 into distearoylphosphatidylethanolamine–polyethylene glycol 2000 (DSPE-PEG2000) micelles using the thin layer evaporation method. The formulation showed efficient encapsulation of RAD001 and a homogeneous colloidal size and stabilised RAD001, with over 95% of activity preserved after 14 days at 37 °C with a total decay only occurring after 98 days. RAD001-loaded DSPE-PEG2000 micelles were unchanged when stored at 4 and 25 °C over the time period investigated. The obtained formulation may represent a suitable platform for expedited clinical translation and effective therapeutic regimens in AD and other neurological diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy.
- Tuberous Sclerosis Association, 00147 Roma, Italy.
- Department of Biochemistry, Desio Hospital, ASST-Brianza, 20832 Desio, Italy.
- Neuroscience Institute of Rosà, 36027 Rosà, Italy.
ORCID-Profile: Alessandro Magini, Roberto Dominici, Stefano Giovagnoli
Förderung
- Fondazione SMuovilavita - Vicenza
- “SMuovilavita Foundation”, NPO, Italy
- “Associazione Sclerosi Tuberosa”, NPO, Italy
- “Associazione Ricerca Alzheimer Lissone ARAL”, NPO, Italy
- “Neuroscience Institute of Rosà”
Zitieren
APA
Gianessi, L., Magini, A., Dominici, R., Giovagnoli, S., & Dolcetta, D. (2023). A Stable Micellar Formulation of RAD001 for Intracerebroventricular Delivery and the Treatment of Alzheimer’s Disease and Other Neurological Disorders. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242417478
Vancouver
Gianessi L, Magini A, Dominici R, Giovagnoli S, Dolcetta D. A Stable Micellar Formulation of RAD001 for Intracerebroventricular Delivery and the Treatment of Alzheimer’s Disease and Other Neurological Disorders. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242417478
BibTeX
@article{Gianessi2023,
author = {Gianessi, Laura and Magini, Alessandro and Dominici, Roberto and Giovagnoli, Stefano and Dolcetta, Diego},
title = {A Stable Micellar Formulation of RAD001 for Intracerebroventricular Delivery and the Treatment of Alzheimer’s Disease and Other Neurological Disorders},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242417478}
}
EUVIMED